Article Details

Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue

Retrieved on: 2022-05-20 20:24:30

Tags for this article:

Click the tags to see associated articles and topics

Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue. View article details on HISWAI: https://www.theglobeandmail.com/business/article-vancouver-biotech-zymeworks-rejects-1050-per-share-hostile-bid-from/

Excerpt

Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue. Sean Silcoff Technology Reporter.

Article found on: www.theglobeandmail.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up